The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

A β-modified phosphoric acid compound precursor that inhibits the progress of a phosphorylation reaction having a partial structure represented by ##STR00001##
where A.sub.1 represents —SR.sub.1, —S—S—R.sub.1, —SeR.sub.1, or —X, where X is a halogen selected from fluoro, chloro, bromo, and iodo; R.sub.1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L.sub.1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L.sub.2 represents an alkyl group having 1 to 20 carbon atoms, or the like; L.sub.1 and L.sub.2 may be linked to each other to form a 4 to 6-membered ring structure; L.sub.1 and L.sub.2 may each have a substituent; and the symbol * represents a bond to be bonded to a phosphate group by phosphorylation. Further, provided are a reaction inhibitor and a medicine, each of which includes the β-modified phosphoric acid compound precursor.

Disclosed herein, inter alia, are compounds, modified nucleotides, compositions, and methods of using the same.

A .sup.99mTc-labeled isonitrile-containing glucose derivative having the general formula [.sup.99mTc-(CNDG).sub.6].sup.+, preparation method and use thereof is disclosed herein. The derivative is centered on .sup.99mTc.sup.+, and the carbon atom of the isonitrile in CNDG coordinates with .sup.99mTc(I) to form a hexacoordinated complex [.sup.99mTc-(CNDG).sub.6].sup.+. The [.sup.99mTc-(CNDG).sub.6].sup.+ derivative was obtained by the synthesis of the ligand CNDG and the preparation of the lyophilized CNDG kit. The derivative of this disclosure has good stability, simple preparation, high uptake and good retention at a tumor site, and high tumor/non-target ratio, and it is a novel .sup.99mTc-labeled isonitrile-containing glucose derivative with excellent performance for tumor imaging. The derivative of this disclosure is advantageous for popularization and application.

The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

Provided is a polymerizable compound represented by a Formula E-1 or Formula E-2 shown in the description. In Formula E-1 or Formula E-2, R.sup.1 represents an alkoxy group, —NR.sup.N.sub.2, a hydroxy group, an aryl group, or an alkyl group, wherein R.sup.N each independently represents a hydrogen atom or an alkyl group having 1 to 10 carbon atoms; n represents an integer from 1 to 5; R.sup.3 represents a hydrogen atom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, a trimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group; and X represents a structure represented by any one of Formula B-1 to Formula B-5 shown in the description.

Provided is an L-glucose derivative represented by General Formula (1) below:

##STR00001## wherein X.sup.1 represents a —SAuR.sup.1 group, and X.sup.2, X.sup.3, X.sup.4 and X.sup.5 each independently represent an —OR.sup.2 group, an —NH.sup.2 group, or a fluorine atom; and R.sup.1 represents a ligand and R.sup.2 represents a hydrogen atom or an organic group.

Provided is an L-glucose derivative represented by General Formula (1) below:

##STR00001## wherein X.sup.1 represents a —SAuR.sup.1 group, and X.sup.2, X.sup.3, X.sup.4 and X.sup.5 each independently represent an —OR.sup.2 group, an —NH.sup.2 group, or a fluorine atom; and R.sup.1 represents a ligand and R.sup.2 represents a hydrogen atom or an organic group.

There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; ##STR00001## where A is a linking group represented as —X—NHCO— where X is a C.sub.1 to C.sub.6 alkylene group, each of R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.10, and R.sub.11 is a hydrogen atom, each of R.sub.3, R.sub.6, and R.sub.9 is a substituent of Formula; R.sub.12 is selected from a group of substituents represented by Formulae, R.sub.13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C.sub.1 to C.sub.6 alkyl groups, and Rd is a hydrogen atom or a C.sub.1 to C.sub.6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.